Deuis Jennifer R, Lim Yu Ling, Rodrigues de Sousa Silmara, Lewis Richard J, Alewood Paul F, Cabot Peter J, Vetter Irina
School of Pharmacy, The University of Queensland, Woolloongabba, Australia (J.R.D., Y.L.L., P.J.C., I.V.); Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia (J.R.D., S.R., R.J.L., P.F.A., I.V.).
Neuro Oncol. 2014 Oct;16(10):1324-32. doi: 10.1093/neuonc/nou048. Epub 2014 Apr 8.
Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on intraplantar administration of cisplatin and oxaliplatin and to systematically evaluate the analgesic efficacy of a range of therapeutics.
Neuropathy was induced by a single intraplantar injection of cisplatin or oxaliplatin in C57BL/6J mice and assessed by quantification of mechanical and thermal allodynia. The pharmacological basis of cisplatin-induced neuropathy was characterized using a range of selective pharmacological inhibitors. The analgesic effects of phenytoin, amitriptyline, oxcarbazepine, mexiletine, topiramate, retigabine, gabapentin, fentanyl, and Ca(2+/)Mg(2+) were assessed 24 hours after induction of neuropathy.
Intraplantar administration of cisplatin led to the development of mechanical allodynia, mediated through Nav1.6-expressing sensory neurons. Unlike intraplantar injection of oxaliplatin, cold allodynia was not observed with cisplatin, consistent with clinical observations. Surprisingly, only fentanyl was effective at alleviating cisplatin-induced mechanical allodynia despite a lack of efficacy in oxaliplatin-induced cold allodynia. Conversely, lamotrigine, phenytoin, retigabine, and gabapentin were effective at reversing oxaliplatin-induced cold allodynia but had no effect on cisplatin-induced mechanical allodynia. Oxcarbazepine, amitriptyline, mexiletine, and topiramate lacked efficacy in both models of acute chemotherapy-induced neuropathy.
This study established a novel animal model of cisplatin-induced mechanical allodynia consistent with the A-fiber neuropathy seen clinically. Systematic assessment of a range of therapeutics identified several candidates that warrant further clinical investigation.
周围神经病变是顺铂和奥沙利铂的主要剂量限制性副作用,目前尚无有效的治疗方法。本研究的目的是在基于足底注射顺铂和奥沙利铂的新型动物模型中评估化疗诱导神经病变的药理机制,并系统评价一系列治疗药物的镇痛效果。
通过在C57BL/6J小鼠足底单次注射顺铂或奥沙利铂诱导神经病变,并通过量化机械性和热性痛觉过敏进行评估。使用一系列选择性药理抑制剂对顺铂诱导神经病变的药理基础进行表征。在诱导神经病变24小时后评估苯妥英、阿米替林、奥卡西平、美西律、托吡酯、瑞替加滨、加巴喷丁、芬太尼和钙/镁的镇痛效果。
足底注射顺铂导致机械性痛觉过敏的发生,由表达Nav1.6的感觉神经元介导。与足底注射奥沙利铂不同,顺铂未观察到冷痛觉过敏,这与临床观察结果一致。令人惊讶的是,尽管对奥沙利铂诱导的冷痛觉过敏无效,但只有芬太尼能有效减轻顺铂诱导的机械性痛觉过敏。相反,拉莫三嗪、苯妥英、瑞替加滨和加巴喷丁能有效逆转奥沙利铂诱导的冷痛觉过敏,但对顺铂诱导的机械性痛觉过敏无效。奥卡西平、阿米替林、美西律和托吡酯在两种急性化疗诱导神经病变模型中均无效。
本研究建立了一种与临床所见A纤维神经病变一致的新型顺铂诱导机械性痛觉过敏动物模型。对一系列治疗药物的系统评估确定了几种值得进一步临床研究的候选药物。